Icosavax Inc (NASDAQ:ICVX) shares are trading higher by 45.63% to $12.99 Thursday morning on continued strength after the company provided a six-month immunogenicity update from its Phase 1/1b trial of IVX-121 against respiratory syncytial virus.
The six-month immunogenicity update from the company’s Phase 1/1b trial of IVX-121 against Respiratory Syncytial Virus (RSV) demonstrated a sustained neutralizing antibody (nAb) response against RSV, lasting at least six months after a single administration of IVX-121.
IVX-121 continued to be generally well-tolerated, with no safety concerns observed in this six-month follow-up and no vaccine-related serious adverse events (SAEs)…Read More
According to data from Benzinga Pro, Icosavax has a 52-week high of $25.63 and a 52-week low of $2.28.
